IL162983A - Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis - Google Patents
Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritisInfo
- Publication number
- IL162983A IL162983A IL162983A IL16298304A IL162983A IL 162983 A IL162983 A IL 162983A IL 162983 A IL162983 A IL 162983A IL 16298304 A IL16298304 A IL 16298304A IL 162983 A IL162983 A IL 162983A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- rheumatoid arthritis
- imatinib
- manufacture
- pharmaceutical compositions
- Prior art date
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title abstract 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 title 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title 1
- 229960002411 imatinib Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0201882.8A GB0201882D0 (en) | 2002-01-28 | 2002-01-28 | Organic compounds |
| PCT/EP2003/000802 WO2003063844A2 (en) | 2002-01-28 | 2003-01-27 | Treatment of rheumatoid arthritis using imatinie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL162983A true IL162983A (en) | 2010-06-16 |
Family
ID=9929858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL162983A IL162983A (en) | 2002-01-28 | 2004-07-12 | Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20060264443A1 (enExample) |
| EP (1) | EP1471916B1 (enExample) |
| JP (1) | JP4398731B2 (enExample) |
| KR (1) | KR101030416B1 (enExample) |
| CN (1) | CN1646130A (enExample) |
| AT (1) | ATE399555T1 (enExample) |
| BR (1) | BR0307286A (enExample) |
| CA (1) | CA2473158C (enExample) |
| DE (1) | DE60321888D1 (enExample) |
| DK (1) | DK1471916T3 (enExample) |
| ES (1) | ES2309299T3 (enExample) |
| GB (1) | GB0201882D0 (enExample) |
| IL (1) | IL162983A (enExample) |
| MX (1) | MXPA04007309A (enExample) |
| NO (1) | NO328255B1 (enExample) |
| NZ (1) | NZ534137A (enExample) |
| PL (1) | PL212137B1 (enExample) |
| PT (1) | PT1471916E (enExample) |
| RU (1) | RU2322238C2 (enExample) |
| SI (1) | SI1471916T1 (enExample) |
| WO (1) | WO2003063844A2 (enExample) |
| ZA (1) | ZA200405323B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003226209B2 (en) * | 2002-03-21 | 2008-10-23 | Dana-Farber Cancer Institute, Inc. | Inhibition of cell death responses induced by oxidative stress |
| US20050130986A1 (en) * | 2003-11-21 | 2005-06-16 | Eklund Kari K. | Treatment of spondylarthropathies |
| US20080248022A1 (en) * | 2004-09-08 | 2008-10-09 | Immunaid Pty Ltd | Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases |
| US20080032989A1 (en) * | 2006-05-31 | 2008-02-07 | Robinson William H | Method of treating inflammatory diseases using tyroskine kinase inhibitors |
| CN102512421B (zh) * | 2011-10-28 | 2013-11-06 | 中国科学院广州生物医药与健康研究院 | 哌嗪酰胺类化合物在制药中的应用 |
| KR101386697B1 (ko) | 2012-06-18 | 2014-04-18 | 아주대학교산학협력단 | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
| RU2580656C1 (ru) * | 2014-11-20 | 2016-04-10 | Закрытое Акционерное Общество "БИОКОМ" | Твердая лекарственная форма гидроксихлорохина немедленного высвобождения и способ ее получения |
| US12173065B2 (en) * | 2018-10-18 | 2024-12-24 | Sinomab Bioscience Limited | Fusion proteins comprising extracellular domain of human CD22 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4316884A (en) * | 1979-01-25 | 1982-02-23 | Adria Laboratories, Inc. | Sustained release pharmaceutical formulation |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US5792476A (en) * | 1996-12-19 | 1998-08-11 | Abigo Medical Ab | Sustained release glucocorticoid pharmaceutical composition |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US6274588B1 (en) * | 1999-05-31 | 2001-08-14 | Hoffmann-La Roche Inc. | 4-phenyl-pyrimidine derivatives |
| CO5200760A1 (es) * | 1999-06-16 | 2002-09-27 | Smithkline Beecham Corp | Antagonistas del receptor de la il-8 ceptor il-8 |
| GB0108606D0 (en) * | 2001-04-05 | 2001-05-23 | Novartis Ag | Organic compounds |
| WO2002083075A2 (en) * | 2001-04-16 | 2002-10-24 | Uab Research Foundation | Akt and regulation of ra synovial fibroblast apoptosis |
| PT1392313E (pt) * | 2001-05-16 | 2007-07-17 | Novartis Ag | Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico |
| EP1401415B1 (en) * | 2001-06-29 | 2006-06-21 | AB Science | Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases |
-
2002
- 2002-01-28 GB GBGB0201882.8A patent/GB0201882D0/en not_active Ceased
-
2003
- 2003-01-27 MX MXPA04007309A patent/MXPA04007309A/es active IP Right Grant
- 2003-01-27 NZ NZ534137A patent/NZ534137A/en not_active IP Right Cessation
- 2003-01-27 JP JP2003563538A patent/JP4398731B2/ja not_active Expired - Fee Related
- 2003-01-27 US US10/502,534 patent/US20060264443A1/en not_active Abandoned
- 2003-01-27 DE DE60321888T patent/DE60321888D1/de not_active Expired - Lifetime
- 2003-01-27 EP EP03704474A patent/EP1471916B1/en not_active Expired - Lifetime
- 2003-01-27 RU RU2004126447/15A patent/RU2322238C2/ru not_active IP Right Cessation
- 2003-01-27 DK DK03704474T patent/DK1471916T3/da active
- 2003-01-27 WO PCT/EP2003/000802 patent/WO2003063844A2/en not_active Ceased
- 2003-01-27 SI SI200331369T patent/SI1471916T1/sl unknown
- 2003-01-27 ES ES03704474T patent/ES2309299T3/es not_active Expired - Lifetime
- 2003-01-27 CN CNA038028808A patent/CN1646130A/zh active Pending
- 2003-01-27 BR BR0307286-0A patent/BR0307286A/pt not_active IP Right Cessation
- 2003-01-27 CA CA2473158A patent/CA2473158C/en not_active Expired - Fee Related
- 2003-01-27 KR KR1020047011580A patent/KR101030416B1/ko not_active Expired - Fee Related
- 2003-01-27 PL PL370264A patent/PL212137B1/pl unknown
- 2003-01-27 PT PT03704474T patent/PT1471916E/pt unknown
- 2003-01-27 AT AT03704474T patent/ATE399555T1/de active
-
2004
- 2004-07-05 ZA ZA2004/05323A patent/ZA200405323B/en unknown
- 2004-07-12 IL IL162983A patent/IL162983A/en not_active IP Right Cessation
- 2004-08-27 NO NO20043585A patent/NO328255B1/no not_active IP Right Cessation
-
2008
- 2008-12-04 US US12/328,013 patent/US20090131382A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1646130A (zh) | 2005-07-27 |
| EP1471916A2 (en) | 2004-11-03 |
| RU2004126447A (ru) | 2005-07-10 |
| US20090131382A1 (en) | 2009-05-21 |
| PT1471916E (pt) | 2008-10-03 |
| KR20040086301A (ko) | 2004-10-08 |
| GB0201882D0 (en) | 2002-03-13 |
| ES2309299T3 (es) | 2008-12-16 |
| PL370264A1 (en) | 2005-05-16 |
| ZA200405323B (en) | 2005-08-31 |
| BR0307286A (pt) | 2004-12-28 |
| HK1072192A1 (en) | 2005-08-19 |
| ATE399555T1 (de) | 2008-07-15 |
| KR101030416B1 (ko) | 2011-04-20 |
| RU2322238C2 (ru) | 2008-04-20 |
| DE60321888D1 (enExample) | 2008-08-14 |
| PL212137B1 (pl) | 2012-08-31 |
| SI1471916T1 (sl) | 2008-12-31 |
| JP2005526022A (ja) | 2005-09-02 |
| EP1471916B1 (en) | 2008-07-02 |
| US20060264443A1 (en) | 2006-11-23 |
| MXPA04007309A (es) | 2005-09-12 |
| WO2003063844A2 (en) | 2003-08-07 |
| WO2003063844A3 (en) | 2004-04-01 |
| NO328255B1 (no) | 2010-01-18 |
| DK1471916T3 (da) | 2008-10-20 |
| JP4398731B2 (ja) | 2010-01-13 |
| CA2473158C (en) | 2013-06-11 |
| NZ534137A (en) | 2007-03-30 |
| NO20043585L (no) | 2004-10-21 |
| CA2473158A1 (en) | 2003-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1826202A (en) | Treatment of gastrointestinal stromal tumors | |
| IL164678A (en) | High-drug tablet containing 4– (4-methylpiprazine – 1-ylamethyl) -n - [(4-methyl-3– (4-pyridin-3-il) pyrimidine-2-ylamino) phenyl] -benzamide or compatible salt Its pharmaceutical and process for its preparation | |
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| MY129772A (en) | Crystal modification of a n-phenyl- 2 - pyrimidineamine derivative, processes for its manufacture and its use | |
| MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
| MX2007000505A (es) | Derivados de oxindol sustituidos y medicamentos que contienen los mismos. | |
| PL1620425T3 (pl) | Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu | |
| IL177005A0 (en) | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
| BR0312873A (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante | |
| IL162983A (en) | Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis | |
| MY146403A (en) | F, g, h, i and k crystal forms of imatinib mesylate | |
| AU2003280191A1 (en) | Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia | |
| GEP20074051B (en) | Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders | |
| NZ543709A (en) | Use of tyrosine kinase inhibitor to treat diabetes | |
| WO2006012958A3 (en) | Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
| WO2004103374A3 (en) | Imatinib combinations for head and neck cancers | |
| AU2003209521A1 (en) | Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas | |
| WO2009069680A1 (ja) | 消化管間質腫瘍（ｇｉｓｔ）を処置するための医薬組成物、ならびに消化管間質腫瘍を患う患者の予後を予測するためのキットおよび方法 | |
| TH64302A (th) | อนุพันธุ์ของควินาโซลีน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |